Flavedon is an anti-anginal medication, which is used for the symptomatic treatment of stable angina pectoris, chest pain caused by decreased oxygen supply due to reduced blood flow to the heart. This medicine is used when patients do not respond adequately to other agents or are intolerant to first-line anti-anginal agents. Flavedon contains Trimetazidine Hydrochloride.
Flavedon is product of Serdia Pharmaceuticals (India) Pvt. Ltd. Serdia has been in existence in India since 1986. Serdia currently employs more than 450 people – of which almost 400 comprise highly competent field force professionals with very sound scientific knowledge. The company is well- respected in the medical fraternity for its original products, strong scientific base and ethical promotion.
They also provide services to the medical profession through the introduction of innovative molecules, information-based medical visits and the organization of reputed scientific meetings.
Angina is a type of chest pain caused by reduced blood flow to the heart. Angina is a symptom of coronary artery disease.
Angina, also called angina pectoris, is often described as squeezing, pressure, heaviness, tightness or pain in your chest. Some people with angina symptoms say angina feels like something is squeezing their chest or a heavy weight lying on their chest. Angina may be a new pain that needs to be checked by a doctor, or recurring pain that goes away with treatment. Although angina is relatively common, it can still be hard to distinguish from other types of chest pain, such as the discomfort of indigestion.
As directed by physician
As directed by physician
Adverse Reactions/ Side Effects
Significant: Movement disorders (e.g. Parkinsonian symptoms, restless leg syndrome, tremors, gait instability). Gastrointestinal disorders: Abdominal pain, dyspepsia, diarrhoea, nausea, vomiting. General disorders and administration site conditions: Asthenia. Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria. Vascular disorders.
Moderate renal impairment, elderly patients, pregnancy. Not indicated for initial treatment of unstable angina, myocardial infarction nor in the pre-hospital phase or during the first days of hospitalisation. This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery.
Parkinson’s disease, parkinsonian symptoms, tremors, restless leg syndrome and other movement related disorders. Severe renal impairment (CrCl <30 mL/min).
Store below 30°C.
Mechanism of Action
Trimetazidine inhibits β-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, thereby enhancing glucose oxidation. By preserving energy metabolism in cells exposed to ischaemia or hypoxia, it prevents decrease in intracellular ATP levels and ensures proper functioning of ionic pumps and transmembrane Na-K flow.
Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.